QLT Inc.

218 articles with QLT Inc.

• QLT Inc. Announces Fourth Quarter and Year End 2010 Results

  3/1/2011

• QLT Inc. Chief Medical Officer Steps Down

  2/23/2011

• QLT Inc. Receives Positive Opinions for Orphan Drug Designation by the European Medicines Agency for QLT091001 to Treat Two Hereditary Blindness Diseases

  2/10/2011

• QLT Inc. Announces Phase II Clinical Trial Results for the Olopatadine Punctal Plug Delivery System (O-PPDS)

  2/9/2011

• QLT Inc. Announces Toronto Stock Exchange Approval of Share Repurchase Program

  12/10/2010

• QLT Inc. Announces Share Repurchase Program

  12/8/2010

• QLT Inc. Swings to Loss, Cuts Visudyne Sales Outlook

  11/4/2010

• QLT Inc. Announces Third Quarter Results for 2010

  11/3/2010

• QLT Inc. Announces Expansion of Phase 1b Study of Oral Synthetic Retinoid Compound

  10/28/2010

• QLT Inc. Announces Second Quarter Results for 2010

  7/27/2010

• QLT Inc. Added to the Russell Global Index

  6/28/2010

• QLT Inc. Eye Drug, Lucentis Cuts Need to Revisit Doctor

  6/22/2010

• QLT Inc. Announces Final Results From Its RADICAL Study Evaluating Verteporfin PDT (Visudyne(R)) Combination Therapy in Exudative AMD

  6/22/2010

• QLT Inc. Release: 12-Month Results From DENALI Study Evaluating verteporfin PDT (Visudyne(R)) Combination Therapy

  6/16/2010

• Valocor Therapeutics, Inc. Acquires Rights to Novel Dermatology Programs from QLT Inc.

  5/25/2010

• QLT Inc. Announces Toronto Stock Exchange Approval of Increased Share Repurchase Program

  5/24/2010

• QLT Inc. Announces Its Intention to Increase Share Repurchase Program

  5/20/2010

• QLT Inc. Announces First Quarter Results for 2010

  5/6/2010

• QLT Inc. Announces Positive Interim Results From Phase 1b Study of its Oral Synthetic Retinoid Compound in Leber Congenital

  4/20/2010

• QLT Inc. Names Dipak Panigrahi, M.D., as Chief Medical Officer

  4/12/2010